LCM
AVIR icon

Laurion Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

Laurion Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-45,000
Closed -$2.78M – 706
2021
Q1 		$2.78M Hold
45,000
– – 0.02% 395
2020
Q4 		$1.88M Buy
+45,000
New +$1.45M 0.01% 347

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AICPI
ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

Laurion Capital Management's AVIR Position: Q2 2021 in Review

Laurion Capital Management sold out of Atea Pharmaceuticals (AVIR) in Q2 2021, closing a stake of 45,000 shares — an estimated $2.78M sold.

Laurion Capital Management first reported a position in AVIR in Q4 2020 and held it in 2 quarters. The position peaked at $2.78M in Q1 2021. 103 funds tracked by Wall St. Rank hold AVIR as of Q2 2021.

  • Laurion Capital Management reported no remaining Atea Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Laurion Capital Management sold 45,000 Atea Pharmaceuticals shares in Q2 2021, an estimated $2.78M.
  • Laurion Capital Management first reported a position in Atea Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Laurion Capital Management's Atea Pharmaceuticals position peaked at $2.78M in Q1 2021.
  • 103 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2021.

Based on Laurion Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.